(Q42875121)

English

Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response

scientific article published on 25 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Coated cross-species antibodies by mannosamine-biotin adduct confer protection against snake venom without eliciting humoral immune response (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

0 references

author name string

Tal Gefen

1

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Jacob Pitcovski

2

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Jacob Vaya

3

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Soliman Khatib

4

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Simi Krispel

5

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

E Dan Heller

6

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Elena Gaberman

7

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Raphael Gorodetsky

8

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Elina Aizenshtein

9

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

language of work or name

0 references

publication date

25 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

8197-8202

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

Passive immunity in prevention and treatment of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Back to the future: antibody-based strategies for the treatment of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Antibodies against viruses: passive and active immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Appropriate therapeutic use of immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Passive antibody therapies: progress and continuing challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Humanized antibodies as potential therapeutic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

The impact of PEGylation on biological therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Chemistry for peptide and protein PEGylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Functionalized Poly(ethylene glycols) for Preparation of Biologically Relevant Conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Disulfide bridge based PEGylation of proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Reduced immunogenicity of beta-lactoglobulin by conjugation with carboxymethyl dextran differing in molecular weight

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Mannosamine-biotin as a novel masking agent for coating IgG for immune response silencing and augmentation of antibody-antigen interaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Snake antivenoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Presynaptic neuromuscular activity of venom from the brown-headed snake (Glyphodon tristis).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Emergency treatment of a snake bite: Pearls from literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Snake venom hemorrhagins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.032

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.09.032

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42875121&oldid=1973072269"